NEW YORK, April 19 (GenomeWeb News) - Incogen said today that it has received a $2 million Phase II grant from the National Cancer Institute to develop its cancer diagnostic software.
The company will work with the
The two-year grant follows on a Phase I grant awarded to Incogen a year ago, which funded the development of a pilot project to analyze proteomics data produced by Ciphergen Biosystems' SELDI platform. In the second phase of the project, Incogen hopes to develop a clinical diagnostic software package for distribution to clinical researchers.
EVMS will produce the data for the project, while W&M and Incogen will analyze the data, the company said.